It binds to GLP-1 receptors found on: Pancreatic -cells Stimulates glucose-dependent insulin secretion Pancreatic -cells Suppresses glucagon release during hyperglycemia Hypothalamic satiety centers Reduces appetite and food intake Gastrointestinal tract Delays gastric emptying, enhancing satiety This multi-site activity leads to improved glycemic control, reduced body weight, and cardiovascular benefits
This guide compares how each format works, who may qualify, and what to discuss with a licensed clinician before starting treatment
That force can damage the peptides
Preparing for Increased Use With millions of patients taking GLP-1 medications, including semaglutide, tirzepatide, liraglutide, and dulaglutide, dental teams will encounter these therapies more frequently in practice
Important: Microdosing has not been evaluated in large randomized clinical trials
It all comes down to what your provider feels is medically most appropriate in your case